164 related articles for article (PubMed ID: 18455282)
21. Patterns of serum type 1 and type 2 immune markers in healthy carriers of HTLV-I.
Birmann BM; Mueller NE; Okayama A; Hsieh CC; Tsubouchi H; Harn D; Stuver SO
J Med Virol; 2006 Jun; 78(6):847-52. PubMed ID: 16628590
[TBL] [Abstract][Full Text] [Related]
22. Serum titers of IgG antibodies against tetanus and diphtheria toxoids and risk of multiple sclerosis.
Massa J; Munger KL; O'Reilly EJ; Levin LI; Ascherio A
J Neuroimmunol; 2009 Mar; 208(1-2):141-2. PubMed ID: 19201486
[TBL] [Abstract][Full Text] [Related]
23. Reduced cell turnover in lymphocytic monkeys infected by human T-lymphotropic virus type 1.
Debacq C; Héraud JM; Asquith B; Bangham C; Merien F; Moules V; Mortreux F; Wattel E; Burny A; Kettmann R; Kazanji M; Willems L
Oncogene; 2005 Nov; 24(51):7514-23. PubMed ID: 16091751
[TBL] [Abstract][Full Text] [Related]
24. Antibody responses in vivo in chromosome instability syndromes with immunodeficiency.
Weemaes CM; The TH; van Munster PJ; Bakkeren JA
Clin Exp Immunol; 1984 Sep; 57(3):529-34. PubMed ID: 6467678
[TBL] [Abstract][Full Text] [Related]
25. [Antibodies to vaccinal antigens in patients with viral hepatitis and acute intestinal infections].
Granitov VM; Starosel'skiĭ DV
Vrach Delo; 1983 Nov; (11):110-2. PubMed ID: 6659441
[No Abstract] [Full Text] [Related]
26. [Diphtheria and tetanus-toxoid vaccination in early infancy].
Schneeweiss B; Wiegand U; Briedigkeit W
Padiatr Padol; 1971 Jun; 6(2):168-80. PubMed ID: 5155256
[No Abstract] [Full Text] [Related]
27. Performance of IgG and IgG1 anti-HTLV-1 reactivity by an indirect immunofluorescence flow cytometric assay for the identification of persons infected with HTLV-1, asymptomatic carriers and patients with myelopathy.
Coelho-dos-Reis JG; Martins-Filho OA; de Brito-Melo GE; Gallego S; Carneiro-Proietti AB; Souza JG; ; Barbosa-Stancioli EF
J Virol Methods; 2009 Sep; 160(1-2):138-48. PubMed ID: 19447144
[TBL] [Abstract][Full Text] [Related]
28. Transient immunoglobulin and antibody production. Occurrence in two patients with common varied immunodeficiency.
Zielinski CC; Mutschlechner R; Schwarz G; Eibl MM
Arch Intern Med; 1983 Oct; 143(10):1937-40. PubMed ID: 6605128
[TBL] [Abstract][Full Text] [Related]
29. Quantitation of anti-tetanus and anti-diphtheria antibodies by enzymoimmunoassay: methodology and applications.
Virella G; Hyman B
J Clin Lab Anal; 1991; 5(1):43-8. PubMed ID: 1999762
[TBL] [Abstract][Full Text] [Related]
30. Antigen-induced suppression of human in vitro pokeweed mitogen-stimulated antibody production.
Stevens RH; Saxon A
Cell Immunol; 1980 Sep; 55(1):85-93. PubMed ID: 7428046
[No Abstract] [Full Text] [Related]
31. The effect of passive immunization against tetanus toxoid in man.
Plassara M; Mandalenaki C; Papathanassiou E; Vrachnou E; Athanassiades P
Immunology; 1978 Sep; 35(3):567-70. PubMed ID: 308931
[TBL] [Abstract][Full Text] [Related]
32. HIV/human T-cell lymphotropic virus coinfection revisited: impact on AIDS progression.
Brites C; Sampalo J; Oliveira A
AIDS Rev; 2009; 11(1):8-16. PubMed ID: 19290030
[TBL] [Abstract][Full Text] [Related]
33. Designed transfer of specific immune responses with bone marrow transplantation.
Saxon A; Mitsuyasu R; Stevens R; Champlin RE; Kimata H; Gale RP
J Clin Invest; 1986 Oct; 78(4):959-67. PubMed ID: 3531239
[TBL] [Abstract][Full Text] [Related]
34. High tetanus and diphtheria antitoxin concentrations in Finnish adults--time for new booster recommendations?
Olander RM; Auranen K; Härkänen T; Leino T
Vaccine; 2009 Aug; 27(39):5295-8. PubMed ID: 19596410
[TBL] [Abstract][Full Text] [Related]
35. Dynamic changes of horse serum T-globulin immunization with snake venoms, tetanus and diphtheria toxoids.
Lee HF; Lee JD; Lee YC
Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi; 1979 Dec; 12(4):127-35. PubMed ID: 583543
[TBL] [Abstract][Full Text] [Related]
36. Cellular and humoral responses to tetanus vaccination in Gabonese children.
van Riet E; Retra K; Adegnika AA; Jol-van der Zijde CM; Uh HW; Lell B; Issifou S; Kremsner PG; Yazdanbakhsh M; van Tol MJ; Hartgers FC
Vaccine; 2008 Jul; 26(29-30):3690-5. PubMed ID: 18539369
[TBL] [Abstract][Full Text] [Related]
37. Immunoglobulin E-suppressing and immunoglobulin G-enhancing tetanus toxoid prepared by conjugation with pullulan.
Mitani S; Yamamoto A; Ikegami H; Usui M; Matuhasi T
Infect Immun; 1982 Jun; 36(3):971-6. PubMed ID: 7095857
[TBL] [Abstract][Full Text] [Related]
38. Preparation of a diphtheria toxin-pullulan conjugate that elicits good IgG antibody production with poor IgE synthesis.
Yamaya S; Yamamoto A; Komiya T; Mizuguchi J; Matuhasi T
Vaccine; 1990 Feb; 8(1):65-9. PubMed ID: 2107646
[TBL] [Abstract][Full Text] [Related]
39. Multiple subsets of anti-tetanus toxoid antibody-producing cells in human peripheral blood differ by size, expression of membrane receptors, and mitogen reactivity.
Thiele CJ; Morrow CD; Stevens RH
J Immunol; 1981 Mar; 126(3):1146-53. PubMed ID: 6970218
[No Abstract] [Full Text] [Related]
40. Human T-cell lymphotropic virus type 1 infective dermatitis emerging in adulthood.
Maragno L; Casseb J; Fukumori LM; Sotto MN; Duarte AJ; Festa-Neto C; Sanches JA
Int J Dermatol; 2009 Jul; 48(7):723-30. PubMed ID: 19570078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
